MediWound (MDWD) Financials: History & Chart

MediWound Ltd.(MDWD)

Biotechnology · Yavne, HM

$13.22-0.29 (-2.18%)

Delayed quote: Oct 6, 2026, 12:54 PM EDT

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Yavne, HM

121 employees

www.mediwound.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ofer Gonen

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	11.86M	3.09M	1.48M	1.87M	5.43M	5.71M	3.96M	5.84M	4.36M
Cost of Goods Sold	10.03M	2.75M	1.15M	1.59M	4.53M	4.37M	3.22M	4.94M	3.68M
Gross Profit	1.83M	337K	323K	278K	896K	1.34M	738K	903K	677K
Gross Profit Margin	15.5%	10.9%	21.9%	14.9%	16.5%	23.5%	18.7%	15.5%	15.5%
Total Operating Expenses	33.61M	9.79M	8.30M	8.09M	7.42M	7.06M	5.96M	6.99M	5.76M
Research & Development	19.03M	5.90M	5.18M	4.48M	3.46M	3.49M	2.89M	2.99M	2.52M
Selling, General & Administrative	14.74M	3.89M	3.56M	3.33M	3.96M	3.57M	3.07M	3.77M	3.23M
Operating Income (EBIT)	-31.78M	-9.46M	-7.98M	-7.81M	-6.53M	-5.72M	-5.22M	-6.08M	-5.08M
Operating Margin	-267.9%	-305.9%	-541.0%	-418.5%	-120.2%	-100.1%	-132.1%	-104.2%	-116.7%
Income Before Tax (EBT)	-20.04M	-7.36M	-2.97M	-7.11M	-2.60M	-13.28M	-721K	-3.89M	-10.26M
Interest Income	7.84M	3.22M	N/A	690K	3.93M	429K	4.50M	2.21M	N/A
Interest Expense	1.12M	1.12M	N/A	N/A	N/A	7.99M	N/A	N/A	5.18M
Other Income/Expense	11.74M	2.10M	5.01M	703K	3.93M	-7.56M	4.50M	2.19M	-5.18M
Net Income	-20.18M	-7.39M	-2.95M	-7.18M	-2.65M	-13.32M	-726K	-3.91M	-10.28M
Income Tax Expense	142K	33K	-17K	73K	53K	38K	5K	18K	21K
Net Profit Margin	-170.1%	-239.1%	-200.1%	-384.7%	-48.8%	-233.3%	-18.4%	-66.9%	-236.1%
EBITDA	-29.89M	-9.06M	-7.60M	-7.12M	-6.11M	-5.32M	-4.87M	-5.69M	-4.72M
EBITDA Margin	-251.9%	-292.9%	-515.4%	-381.5%	-112.5%	-93.2%	-123.1%	-97.4%	-108.4%
Depreciation & Amortization	1.89M	402K	378K	690K	418K	394K	358K	397K	361K
EPS Basic	-1.60	-0.57	-0.23	-0.56	-0.24	-1.23	-0.07	-0.36	-0.98
EPS Diluted	-1.60	-0.57	-0.23	-0.56	-0.24	-1.23	-0.07	-0.36	-0.98
Weighted Average Basic Shares	12.88M	12.88M	12.87M	12.83M	11.02M	10.84M	10.37M	10.79M	10.51M
Weighted Average Diluted Shares	12.88M	12.88M	12.87M	12.83M	11.02M	10.84M	10.80M	10.79M	10.51M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	16.96M	20.22M	18.69M	26.50M	23.76M	21.76M	31.79M	3.40M
Cost of Goods Sold	13.71M	17.59M	15.11M	13.33M	14.99M	14.22M	11.85M	2.09M
Gross Profit	3.25M	2.63M	3.58M	13.16M	8.77M	7.54M	19.94M	1.31M
Gross Profit Margin	19.2%	13.0%	19.1%	49.7%	36.9%	34.7%	62.7%	38.6%
Total Operating Expenses	28.53M	22.02M	19.08M	20.83M	19.99M	16.39M	15.45M	5.27M
Research & Development	14.32M	8.88M	7.47M	10.18M	10.26M	7.70M	4.97M	4.07M
Selling, General & Administrative	13.93M	12.91M	11.38M	10.37M	9.45M	8.50M	9.06M	7.94M
Operating Income (EBIT)	-25.28M	-19.38M	-15.50M	-7.66M	-11.22M	-8.84M	4.49M	-3.96M
Operating Margin	-149.1%	-95.8%	-83.0%	-28.9%	-47.2%	-40.6%	14.1%	-116.4%
Income Before Tax (EBT)	-23.71M	-30.16M	-6.53M	-19.52M	-13.52M	-9.28M	2.07M	-5.67M
Interest Income	1.86M	2.05M	2.34M	270K	11K	297K	434K	412K
Interest Expense	663K	561K	335K	162K	167K	200K	207K	N/A
Other Income/Expense	1.57M	-10.78M	8.97M	-11.86M	-2.30M	-436K	-2.43M	-1.71M
Net Income	-23.88M	-30.22M	-6.72M	-19.60M	-13.55M	-9.20M	4.96M	-1.06M
Income Tax Expense	169K	61K	185K	78K	27K	0.00	0.00	0.00
Net Profit Margin	-140.8%	-149.5%	-35.9%	-74.0%	-57.0%	-42.3%	15.6%	-31.1%
EBITDA	-23.42M	-17.90M	-14.20M	-6.39M	-9.98M	-7.75M	5.64M	-3.38M
EBITDA Margin	-138.1%	-88.5%	-76.0%	-24.1%	-42.0%	-35.6%	17.7%	-99.5%
Depreciation & Amortization	1.86M	1.48M	1.30M	1.27M	1.24M	1.09M	1.15M	577K
EPS Basic	-2.10	-3.03	-0.75	-3.93	-3.48	-2.38	1.26	-0.28
EPS Diluted	-2.10	-3.03	-0.75	-3.93	-3.48	-2.38	1.26	-0.28
Weighted Average Basic Shares	11.38M	9.96M	9.01M	4.99M	3.89M	3.89M	3.88M	3.87M
Weighted Average Diluted Shares	11.38M	9.96M	9.01M	4.99M	3.89M	3.89M	3.88M	3.87M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.